Personalis (PSNL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
12 May, 2026Opening remarks and agenda
CEO welcomed attendees, introduced board and management, and outlined the virtual meeting format with Q&A opportunities.
Formal business included three proposals: director elections, auditor ratification, and executive compensation approval.
Board and executive committee updates
Board members and executive team were introduced, including external legal counsel and independent auditors.
Shareholder proposals
No stockholder nominations for director were submitted; nominations were closed.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Personalis
- Q2 2026 revenue up 30% YoY, clinical revenue soared 442%, Tempus merger announced.PSNL
Q2 2026 - Clinical test volumes soared 258% year-over-year as Medicare coverage expanded, despite revenue decline.PSNLQ1 2026
- Virtual annual meeting to vote on directors, auditor, and executive pay, all board-recommended.PSNLProxy filing
- Proxy covers director elections, auditor ratification, pay-for-performance, and key related party deals.PSNLProxy filing
- Clinical test volume soared nearly 400% in 2025, with 2026 revenue guided to $78–$80 million.PSNLQ4 2025
- Q3 revenue up 41% year-over-year, guidance raised, cash runway extended to 2027.PSNLQ3 2024
- Q2 revenue up 35% year-over-year, guidance raised, net loss narrowed, but risks remain.PSNLQ2 2024
- Ultra-sensitive ctDNA testing detects cancer recurrence and therapy response earlier than current methods.PSNLStatus Update
- Q1 2025 revenue up 6% to $20.6M, pharma revenue up 39%, net loss $15.8M, cash $185.7M.PSNLQ1 2025